In Preparation for Biosimilar "Switch" Policy: How to Mitigate the Nocebo Effect

J Cutan Med Surg. 2022 Mar-Apr;26(2):203-205. doi: 10.1177/12034754211048674. Epub 2021 Oct 14.
No abstract available

Keywords: adalimumab; biologics; biosimilars; etanercept; infliximab; nocebo.

MeSH terms

  • Adalimumab
  • Biosimilar Pharmaceuticals* / therapeutic use
  • Etanercept
  • Humans
  • Infliximab
  • Nocebo Effect
  • Policy

Substances

  • Biosimilar Pharmaceuticals
  • Infliximab
  • Adalimumab
  • Etanercept